Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy.
Journal
Drugs in R&D
ISSN: 1179-6901
Titre abrégé: Drugs R D
Pays: New Zealand
ID NLM: 100883647
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
accepted:
01
09
2021
pubmed:
26
9
2021
medline:
23
11
2021
entrez:
25
9
2021
Statut:
ppublish
Résumé
Immune checkpoint inhibitors have been demonstrated to improve overall survival. Atypical patterns of response have been reported, including dissociated response (DR). We evaluated the prevalence of DR. Patients had to have a baseline computed tomography (CT) scan and at least one follow-up CT scan and two target lesions (TLs). Three types of DR were evaluated using RECIST1.1: DR1, defined as at least one progressive and one responding TL; DR2, defined as at least one progressive and one stable TL; and DR3, defined as at least one stable and one responding TL. A total of 1244 measurements of 272 TLs were performed in 100 patients. Forty-nine out of the 272 TLs (18%) had received old or recent radiotherapy, and 42 (15%) had been biopsied. An objective response was observed in 22 patients (22%) and on 52 TLs (19%). DR1 were observed in 8% of patients. At the tumor measurement level, the response rate was lower in the case of prior radiotherapy (29% vs 34%, p = 0.01) and higher in the case of prior biopsy (40% vs 32%, p = 0.02). A DR was observed in 8% of patients. Response rate was lower in the case of prior radiotherapy and higher in the case of prior biopsy.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint inhibitors have been demonstrated to improve overall survival. Atypical patterns of response have been reported, including dissociated response (DR). We evaluated the prevalence of DR.
PATIENTS AND METHODS
METHODS
Patients had to have a baseline computed tomography (CT) scan and at least one follow-up CT scan and two target lesions (TLs). Three types of DR were evaluated using RECIST1.1: DR1, defined as at least one progressive and one responding TL; DR2, defined as at least one progressive and one stable TL; and DR3, defined as at least one stable and one responding TL.
RESULTS
RESULTS
A total of 1244 measurements of 272 TLs were performed in 100 patients. Forty-nine out of the 272 TLs (18%) had received old or recent radiotherapy, and 42 (15%) had been biopsied. An objective response was observed in 22 patients (22%) and on 52 TLs (19%). DR1 were observed in 8% of patients. At the tumor measurement level, the response rate was lower in the case of prior radiotherapy (29% vs 34%, p = 0.01) and higher in the case of prior biopsy (40% vs 32%, p = 0.02).
CONCLUSIONS
CONCLUSIONS
A DR was observed in 8% of patients. Response rate was lower in the case of prior radiotherapy and higher in the case of prior biopsy.
Identifiants
pubmed: 34562258
doi: 10.1007/s40268-021-00362-3
pii: 10.1007/s40268-021-00362-3
pmc: PMC8602606
doi:
Substances chimiques
Immunologic Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
399-406Informations de copyright
© 2021. The Author(s).
Références
J Cancer Res Clin Oncol. 2015 Nov;141(11):1985-94
pubmed: 25910988
Cancer Immunol Res. 2017 May;5(5):417-424
pubmed: 28411193
J Natl Cancer Inst. 2013 Feb 20;105(4):256-65
pubmed: 23291374
Cancers (Basel). 2019 Jan 23;11(2):
pubmed: 30678111
Int J Mol Sci. 2018 Dec 21;20(1):
pubmed: 30577587
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Immunotherapy. 2012 Nov;4(11):1081-5
pubmed: 23194355
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Cancer Immunol Res. 2015 Jun;3(6):610-9
pubmed: 25701325
Cancer Immunol Res. 2018 Jun;6(6):630-635
pubmed: 29622582
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
J Exp Med. 2007 Jan 22;204(1):49-55
pubmed: 17210731
Surg Oncol. 2018 Dec;27(4):637-641
pubmed: 30449485
Oncoimmunology. 2016 Aug 19;5(9):e1214788
pubmed: 27757312
Eur J Cancer. 2016 Jul;62:138-45
pubmed: 27237360
Science. 2015 Nov 20;350(6263):981-5
pubmed: 26472762
J Clin Oncol. 2019 Feb 1;37(4):318-327
pubmed: 30557521
Cancer. 2016 Jun 1;122(11):1659-71
pubmed: 26914620
Br J Radiol. 2017 Aug;90(1076):20170157
pubmed: 28541096
Curr Oncol. 2019 Feb;26(1):e81-e93
pubmed: 30853813
Oncotarget. 2017 Aug 7;8(59):100708-100716
pubmed: 29246014
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
Eur J Cancer. 2018 Jan;88:38-47
pubmed: 29182990
Ann Oncol. 2017 Dec 1;28(suppl_12):xii33-xii43
pubmed: 29253115
Ann Oncol. 2019 Mar 1;30(3):385-396
pubmed: 30657859
J Clin Oncol. 2018 Jun 1;36(16):1611-1618
pubmed: 29437535
J Clin Oncol. 2014 Dec 1;32(34):3824-30
pubmed: 25349291
J Natl Compr Canc Netw. 2015 Oct;13(10):1225-31
pubmed: 26483062
Nat Rev Clin Oncol. 2015 Oct;12(10):584-96
pubmed: 26122183